UK Markets close in 4 hrs 19 mins
  • FTSE 100

    7,720.69
    -64.18 (-0.82%)
     
  • FTSE 250

    19,773.97
    -163.23 (-0.82%)
     
  • AIM

    864.27
    -4.89 (-0.56%)
     
  • GBP/EUR

    1.1369
    -0.0010 (-0.09%)
     
  • GBP/USD

    1.2324
    -0.0030 (-0.2452%)
     
  • BTC-GBP

    18,584.66
    -283.18 (-1.50%)
     
  • CMC Crypto 200

    519.39
    -18.48 (-3.44%)
     
  • S&P 500

    4,017.77
    -52.79 (-1.30%)
     
  • DOW

    33,717.09
    -260.99 (-0.77%)
     
  • CRUDE OIL

    77.01
    -0.89 (-1.14%)
     
  • GOLD FUTURES

    1,919.20
    -20.00 (-1.03%)
     
  • NIKKEI 225

    27,327.11
    -106.29 (-0.39%)
     
  • HANG SENG

    21,842.33
    -227.40 (-1.03%)
     
  • DAX

    15,041.78
    -84.30 (-0.56%)
     
  • CAC 40

    7,045.75
    -36.26 (-0.51%)
     

Orion publishes Financial Statement Release for 2022 on Thursday 9 February 2023

Orion Oyj
Orion Oyj

ORION CORPORATION
PRESS RELEASE
26 January 2023 at 12.00 EET

Orion publishes Financial Statement Release for 2022 on Thursday 9 February 2023

Orion will publish Financial Statement Release for 2022 on Thursday, 9 February 2023 at approximately 12.00 noon EET. The report and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing.

Webcast and conference call

A webcast and a conference call for analysts, investors and media representatives will be held on Thursday, 9 February 2023 at 13.30 EET.

A link to the live webcast is available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.

Confenrence call can be joined by registering through the following link:
http://palvelu.flik.fi/teleconference/?id=1009425

Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue.

Questions can also be presented in writing through the question form of the webcast.

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.


Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.